Medicare’s Low Uptake of New Alzheimer’s Drugs Leaves Spending Forecasts Unchanged
Medicare’s spending projections for new Alzheimer’s drugs Leqembi and Kisunla have been slashed due to minimal uptake, with no significant spending ex...
Medicare’s spending projections for new Alzheimer’s drugs Leqembi and Kisunla have been slashed due to minimal uptake, with no significant spending ex...
Medicare spending on recently approved Alzheimer’s drugs Leqembi and Kisunla remains far below federal projections. Experts cite challenges such as di...